Floatz logo

FLUTICASONE

Multiple Myeloma and Plasma Cell Neoplasm

Roswell Park Cancer InstituteSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Multiple Myeloma and Plasma Cell Neoplasm cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
CYCLOSPORIN A
Seoul National University Hospital
Phase 3BBB
Romidepsin
M.D. Anderson Cancer Center
Phase 4BBB

View all 50 →

Same molecule, other indications

FLUTICASONE is also rated in:

Unspecified Adult Solid Tumor, Protocol SpecificDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic Phase Chronic Myelogenous LeukemiaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →